{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:53:17Z","timestamp":1794358397852,"version":"4.9.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA-BC-010816"],"award-info":[{"award-number":["ZIA-BC-010816"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.xcrm.2023.100938","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T11:46:03Z","timestamp":1676029563000},"page":"100938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma"],"prefix":"10.1016","volume":"4","author":[{"given":"Nishanth Ulhas","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Stephen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram Alexander","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chimene","family":"Kesserwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro C.","family":"Hermida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Sang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idrees","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lebensohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjistha","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Ruppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4012-3633","authenticated-orcid":false,"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.100938_bib1","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2023.100938_bib2","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.21037\/tlcr.2019.12.15","article-title":"Peritoneal mesothelioma","volume":"9","author":"Greenbaum","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2023.100938_bib5","first-page":"566","article-title":"The mortality of amphibole miners in South Africa, 1946-80","volume":"49","author":"Sluis-Cremer","year":"1992","journal-title":"Br. J. Ind. Med."},{"key":"10.1016\/j.xcrm.2023.100938_bib6","first-page":"971","article-title":"Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma","volume":"28","author":"Chang","year":"2017","journal-title":"Cancer Causes Control."},{"key":"10.1016\/j.xcrm.2023.100938_bib7","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cam4.656","article-title":"Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database","volume":"5","author":"Farioli","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.xcrm.2023.100938_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10937404.2016.1195322","article-title":"Environmental risk of mesothelioma in the United States: an emerging concern-epidemiological issues","volume":"19","author":"Baumann","year":"2016","journal-title":"J.\u00a0Toxicol. Environ. Health B Crit. Rev."},{"key":"10.1016\/j.xcrm.2023.100938_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.100938_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2023.100938_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.canlet.2016.05.011","article-title":"CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma","volume":"378","author":"Betti","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2023.100938_bib12","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib14","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/JTO.0b013e31817c73ec","article-title":"Single-agent pemetrexed for chemona\u00efve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program","volume":"3","author":"Taylor","year":"2008","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib17","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib18","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib19","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.xcrm.2023.100938_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.100938_bib22","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","article-title":"Phase II study of vinorelbine in patients with malignant pleural mesothelioma","volume":"18","author":"Steele","year":"2000","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2023.100938_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1078-0432.CCR-0607-3","article-title":"Gene expression profiles predict survival and progression of pleural mesothelioma","volume":"10","author":"Pass","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/jnci\/95.8.598","article-title":"Using gene expression ratios to predict outcome among patients with mesothelioma","volume":"95","author":"Gordon","year":"2003","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2023.100938_bib26","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"L\u00f3pez-R\u00edos","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13073-019-0631-0","article-title":"Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma","volume":"11","author":"Ladanyi","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.xcrm.2023.100938_bib28","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.100938_bib29","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2023.100938_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.xcrm.2023.100938_bib31","doi-asserted-by":"crossref","first-page":"660039","DOI":"10.3389\/fonc.2021.660039","article-title":"Tumor immune microenvironment and genetic alterations in mesothelioma","volume":"11","author":"Hiltbrunner","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib32","doi-asserted-by":"crossref","first-page":"e2025109","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2023.100938_bib33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J.\u00a0Am. Stat. Assoc."},{"key":"10.1016\/j.xcrm.2023.100938_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2014.08.004","article-title":"Identification of actionable mutations in malignant pleural mesothelioma","volume":"86","author":"Shukuya","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.100938_bib35","first-page":"6","article-title":"Expression status of candidate genes in mesothelioma tissues and cell lines","volume":"771","author":"Melaiu","year":"2015","journal-title":"Mutat. Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib36","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky973","article-title":"CORUM: the comprehensive resource of mammalian protein complexes-2019","volume":"47","author":"Giurgiu","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkx1013","article-title":"TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions","volume":"46","author":"Han","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2023.100938_bib40","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2023.100938_bib41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2023.100938_bib42","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","article-title":"Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1","volume":"5","author":"Lee","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2023.100938_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2023.100938_bib44","doi-asserted-by":"crossref","first-page":"101192","DOI":"10.1016\/j.isci.2020.101192","article-title":"Immunosuppressive functions of M2 macrophages derived from iPSCs of patients with ALS and healthy controls","volume":"23","author":"Zhao","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.xcrm.2023.100938_bib45","doi-asserted-by":"crossref","first-page":"e8323","DOI":"10.15252\/msb.20188323","article-title":"Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy","volume":"15","author":"Sahu","year":"2019","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.xcrm.2023.100938_bib46","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.cell.2021.03.030","article-title":"Synthetic lethality-mediated precision oncology via the tumor transcriptome","volume":"184","author":"Lee","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2023.100938_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib48","first-page":"4000","article-title":"Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication","volume":"60","author":"Soria","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/carcin\/bgm269","article-title":"Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis","volume":"29","author":"Song","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.xcrm.2023.100938_bib50","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.18632\/oncotarget.13653","article-title":"Prognostic role of cyclin B1 in solid tumors: a meta-analysis","volume":"8","author":"Ye","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2023.100938_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tcb.2012.10.011","article-title":"A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis","volume":"23","author":"D'Angiolella","year":"2013","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.xcrm.2023.100938_bib52","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1083\/jcb.200302129","article-title":"NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization","volume":"162","author":"Raemaekers","year":"2003","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.xcrm.2023.100938_bib53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.yexcr.2018.03.039","article-title":"NUSAP1 gene silencing inhibits cell proliferation, migration and invasion through inhibiting DNMT1 gene expression in human colorectal cancer","volume":"367","author":"Han","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib54","doi-asserted-by":"crossref","first-page":"29935","DOI":"10.18632\/oncotarget.15604","article-title":"NUSAP1 promotes invasion and metastasis of prostate cancer","volume":"8","author":"Gordon","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2023.100938_bib55","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.12659\/MSM.910364","article-title":"Nucleolar and spindle associated protein 1 (NUSAP1) inhibits cell proliferation and enhances susceptibility to epirubicin in invasive breast cancer cells by regulating cyclin D kinase (CDK1) and DLGAP5 expression","volume":"24","author":"Zhang","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.xcrm.2023.100938_bib56","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/onc.2012.69","article-title":"MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4","volume":"32","author":"Agarwal","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2023.100938_bib57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10585-015-9706-5","article-title":"MTBP inhibits migration and metastasis of hepatocellular carcinoma","volume":"32","author":"Bi","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.xcrm.2023.100938_bib58","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1007\/s10620-015-3824-4","article-title":"MTBP promotes the invasion and metastasis of hepatocellular carcinoma by enhancing the MDM2-mediated degradation of E-cadherin","volume":"60","author":"Lu","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.xcrm.2023.100938_bib59","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","article-title":"Atlas of clinically distinct cell states and ecosystems across human solid tumors","volume":"184","author":"Luca","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2023.100938_bib60","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2023.100938_bib61","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1038\/s41467-021-24164-y","article-title":"Notch signaling and efficacy of PD-1\/PD-L1 blockade in relapsed small cell lung cancer","volume":"12","author":"Roper","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.100938_bib62","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","article-title":"Variant Review with the integrative genomics viewer","volume":"77","author":"Robinson","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100938_bib63","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2017-03-735654","article-title":"The NCI Genomic Data Commons as an engine for precision medicine","volume":"130","author":"Jensen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.100938_bib64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2023.100938_bib65","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2023.100938_bib66","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O'Neil","year":"2017","journal-title":"Nat. Rev. Genet."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:47:38Z","timestamp":1770828458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2666379123000307"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.100938","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.100938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"100938"}}